Search Results - "Senapedis, W."

KPT-8602, a second-generation inhibitor of XPO1-mediated nuclear export, is well tolerated and highly active against AML blasts and leukemia-initiating cells by Etchin, J, Berezovskaya, A, Conway, A S, Galinsky, I A, Stone, R M, Baloglu, E, Senapedis, W, Landesman, Y, Kauffman, M, Shacham, S, Wang, J C Y, Look, A T

“…Acute myeloid leukemia (AML) is a clonal hematologic malignant disease of developing myeloid cells that have acquired aberrant survival, uncontrolled…”
Get full text

CRM1 inhibition induces tumor cell cytotoxicity and impairs osteoclastogenesis in multiple myeloma: molecular mechanisms and therapeutic implications by Tai, Y-T, Landesman, Y, Acharya, C, Calle, Y, Zhong, M Y, Cea, M, Tannenbaum, D, Cagnetta, A, Reagan, M, Munshi, A A, Senapedis, W, Saint-Martin, J-R, Kashyap, T, Shacham, S, Kauffman, M, Gu, Y, Wu, L, Ghobrial, I, Zhan, F, Kung, A L, Schey, S A, Richardson, P, Munshi, N C, Anderson, K C

“…The key nuclear export protein CRM1/XPO1 may represent a promising novel therapeutic target in human multiple myeloma (MM). Here we showed that chromosome…”
Get full text

Targeting the vulnerability to NAD+ depletion in B-cell acute lymphoblastic leukemia by Takao, S, Chien, W, Madan, V, Lin, D-C, Ding, L-W, Sun, Q-Y, Mayakonda, A, Sudo, M, Xu, L, Chen, Y, Jiang, Y-Y, Gery, S, Lill, M, Park, E, Senapedis, W, Baloglu, E, Müschen, M, Koeffler, H P

“…Although substantial progress has been made in the treatment of B-cell acute lymphoblastic leukemia (B-ALL), the prognosis of patients with either refractory…”
Get full text

Eltanexor (KPT-8602), a second-generation selective inhibitor of nuclear export (SINE) compound, in patients with metastatic colorectal cancer (mCRC) by Hays, J., Zhang, J., Berlin, J.D., O'Hara, M., Shah, M.A., Reichmann, W., Senapedis, W., Achour, H., Baloglu, E., Shacham, S., Kauffman, M.

Get full text

480 Identification of novel small molecules as selective PAK4 allosteric modulators (PAMs) by stable isotope labeling of amino acids in cells (SILAC) by Senapedis, W, Landesman, Y, Schenone, M, Karger, B, Wu, S, Shacham, S, Baloglu, E

Get full text

247 Selective inhibitors of nuclear export (SINE) block the expression of DNA damage repair proteins and sensitize cancer cells to DNA damage therapeutic agents by Kashyap, T, Crochiere, M, Friedlander, S, Klebanov, B, Senapedis, W, Baloglu, E, del Alamo, D, Tamir, S, Rashal, T, McCauley, D, Carlson, R, Kauffman, M, Shacham, S, Landesman, Y

Get full text

492 Quantification of exportin-1 (XPO1) occupancy by selective inhibitors of nuclear export (SINE) by Crochiere, M, Klebanov, B, Baloglu, E, Kalid, O, Kashyap, T, Senapedis, W, del Alamo, D, Tamir, S, McCauley, D, Carlson, R, Kauffman, M, Shacham, S, Landesman, Y

Get full text

P-307 Modulation of the MYC oncogene using programmable epigenetic mRNA therapeutics as a novel therapy for hepatocellular carcinoma by Senapedis, W., Gallagher, K., Figueroa, E., Farelli, J., O'Donnell, C., Newman, J., McCauley, T.

Get full text

Expression of wild type and mutant TSC2, but not TSC1, causes an increase in the G1 fraction of the cell cycle in HEK293 cells by Khare, L, Astrinidis, A, Senapedis, W, Adams, P D, Henske, E Petri

Get full text

LBA23Eltanexor (KPT-8602), a second-generation selective inhibitor of nuclear export (SINE) compound, in patients with metastatic colorectal cancer (mCRC) by Hays, J, Zhang, J, Berlin, J D, O'Hara, M, Shah, M A, Reichmann, W, Senapedis, W, Achour, H, Baloglu, E, Shacham, S, Kauffman, M

Get full text

A first in human phase 1 study of KPT-9274, a first in class dual inhibitor of PAK4 and NAMPT, in patients with advanced solid malignancies or NHL by Naing, A., Leong, S., Pishvaian, M.J., Razak, A.R.A., Mahipal, A., Berlin, J., Cho, D., Senapedis, W., Shacham, S., Kauffman, M., Ellis, J., Meade, J., Baloglu, E.

Get full text

386PPRECLINICAL EVALUATION OF NOVEL PAK4 ALLOSTERIC MODULATORS AGAINST TRIPLE NEGATIVE BREAST CANCER by Senapedis, W., McCauley, D., Landesman, Y., Kalid, O., Ellis, J., Carlson, R., Shacham, S., Baloglu, E.

“…Abstract Aim: Triple Negative Breast Cancer (TNBC) is characterized by a lack of receptors for estrogen (ER), progesterone (PR), and hormone epidermal growth…”
Get full text

Preclinical Evaluation of Novel Pak4 Allosteric Modulators Against Triple Negative Breast Cancer by Senapedis, W., McCauley, D., Landesman, Y., Kalid, O., Ellis, J., Carlson, R., Shacham, S., Baloglu, E.

Get full text

Hamartin, the tuberous sclerosis complex 1 gene product, interacts with polo-like kinase 1 in a phosphorylation-dependent manner by Astrinidis, Aristotelis, Senapedis, William, Henske, Elizabeth P.

“…Tuberous sclerosis complex (TSC) is a tumor suppressor gene syndrome caused by mutations in TSC1 and TSC2. Hamartin and tuberin, the products of TSC1 and TSC2,…”
Get full text

Cell Cycle-regulated Phosphorylation of Hamartin, the Product of the Tuberous Sclerosis Complex 1 Gene, by Cyclin-dependent Kinase 1/Cyclin B by Astrinidis, Aristotelis, Senapedis, William, Coleman, Thomas R., Henske, Elizabeth Petri

“…Tuberous sclerosis complex is a tumor suppressor gene syndrome whose manifestations can include seizures, mental retardation, and benign tumors of the brain,…”
Get full text